We have raised $20m in our Series A.
9 April 2024
A year after our last funding announcement, I'm excited and proud to share with you that Reshape has secured a $20 million Series A investment, marking one of the largest of its kind in the lab automation space.
This investment, led by Astanor Ventures alongside R7, ACME, Y Combinator, Unity Co-Founder Nicholas Francis, and Per Falholt, is not just a testament to what we've achieved since our inception in Copenhagen in 2018, but a clear signal of the trust and expectations placed upon us by some of the most forward-thinking investors in the biotech space.
When I founded Reshape together with Magnus and Daniel, we were driven by a singular vision: to revolutionize the way biological research is conducted by introducing AI and robotics capable of automating visual experiments with precision and speed. Today, our technology is empowering researchers at top-tier institutions like Syngenta and the University of Oxford, saving over 500,000 hours annually that would otherwise be lost to manual processes. This is not just about efficiency; it's about accelerating our collective journey towards groundbreaking scientific discoveries that can help us tackle some of the biggest global issues we face today.
To me and everyone here at Reshape, this has been a crazy journey. We've demonstrated not just the viability of our technology, but its critical importance to the future of biotech, agriculture, and food R&D. Our platform's ability to capture and analyze data has fundamentally changed the game, turning the slow, error-prone process of biological analysis into a precise, scalable operation.
This new round of funding will be the fuel for our next phase of growth. We're setting our sights on expanding our operations in the US, that will not only bring our technology to more researchers and companies, but also solidify our presence in one of the world's most important scientific environments. We're also focusing on attracting top talent globally, individuals who share our passion for pursuing a new era of R&D that's faster, more accurate, and capable of addressing the complex challenges facing our world.
To our investors, both new and returning, thank you for believing in Reshape's team & mission. Your expertise in scaling deep and frontier tech companies will be invaluable as we embark on this next chapter. And to the entire Reshape team, this moment is a reflection of our hard work, dedication, and belief in a future where our technology can truly make a difference. Thank you.
As we move forward, I'm reminded of the complexity of biology and the transformative power of our platform to make sense of it. The potential to accelerate the pace of discovery and development across biotech, agriculture, and food sectors is enormous—not just for improving research efficiency, but for building a more sustainable and biodiverse planet.
Onwards to a future where every laboratory is empowered to achieve more, faster, and with greater precision. Here's to scaling new heights together.
– Carl-Emil Grøn, CEO & Co-Founder of Reshape
p.s. We're hiring - have a look at our open positions here!
For further information, please contact:
Jim Verho, Marketing Lead
jve@reshapebiotech.com
